, and Wisconsin (31). Most (64%) patients were male; median age was 63 (range 15-94) years; and all 69 patients reported likely tick exposure in Minnesota or Wisconsin. Fever, malaise, thrombocytopenia, and lymphopenia were the most common symptoms. Sixteen (23%) patients were hospitalized (median 4 days); all recovered, and 96% received doxycycline. Infection with the EML pathogen should be considered for persons reporting tick exposure in Minnesota or Wisconsin. E hrlichiosis and anaplasmosis are emerging tickborne zoonoses caused by Ehrlichia spp. and Anaplasma phagocytophilum, respectively (1) (2) (3) (4) . These gram-negative obligate intracellular bacteria infect leukocytes and cause febrile illness in humans (1, 3) . In the United States, most infections occur during May-August, months with peak human exposure to hard tick vectors (3) . The signs, symptoms, and clinical course of ehrlichiosis and anaplasmosis are similar; >50% of patients have fever, headache, chills, malaise, myalgia, and nausea, the most common signs and symptoms (5) . Vomiting, diarrhea, cough, arthralgia, and confusion are less frequently reported (3, 6) . Rashes are infrequently reported among patients with anaplasmosis, but ≈60% of children and 30% of adults with ehrlichiosis report rash (7) . Leukopenia, thrombocytopenia, and elevated alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase are common laboratory findings (3) . Severe complications of anaplasmosis and ehrlichiosis are rare and may include renal failure, pneumonia, acute respiratory distress syndrome, neurologic disorder, and intravascular coagulation (8, 9) . Hospitalization rates are high (ehrlichiosis 49% and anaplasmosis 36%) (1); fatality rates are <1% among patients with anaplasmosis and 1.8% among patients with ehrlichiosis (7, 10) . Elderly and immunocompromised patients, including those with HIV infection and those receiving immunosuppressive therapy for malignancies, are at greatest risk for severe disease (3) .
Anaplasmosis is reported primarily in temperate regions of North America, Europe, and Asia (8, 9 
Acute Phase Serologic Testing and Peripheral Blood Film Examination
Patient serum samples were tested for IgG-class antibodies reacting to A. phagocytophilum and E. chaffeensis at the Mayo Clinic, as previously described (11) . Test results with reciprocal titers >64 were considered positive. Acutephase samples were defined as those collected within 10 days of illness onset, and convalescent-phase samples were defined as samples collected >10 days after symptom onset. Conventional thin blood films created from selected patient samples were stained with Wright-Giemsa and examined for evidence of intraleukocytic morulae.
Patient Information
Demographic, clinical, and epidemiologic information was obtained from health care providers of patients whose samples tested positive by PCR for the EML pathogen; standardized case report forms from the Minnesota and Wisconsin health departments were used to collect data. State health departments obtained and reviewed medical records for hospitalized patients or those treated in an emergency department. Patients were also interviewed by local and state health department staff, who used an investigation questionnaire to collect additional clinical information and travel and tick exposure history.
Results

Real-Time PCR Testing and Sequence Analysis
During 2004-2013, of 75,077 patient samples tested by MML (n = 63,185), Mayo Clinic Health System-Eau Claire (n = 5,722), and Marshfield Clinic Laboratories (n = 6,170), blood samples from 69 patients tested positive for the EML pathogen, including 4 previously reported patients (11) . Sequence analysis of the groEL gene was performed for 64 available samples, and results showed that the amplified regions had 100% homology to each other and 98% homology to E. muris, thus confirming identification as the EML pathogen.
Of the 69 positive results, 64 (93%) were detected among 39,981 samples submitted from health care providers in Minnesota (33 positive results) and Wisconsin (31 positive results) ( Figure 1 
Acute Phase Serologic Testing and Peripheral Blood Film Examination
Of the 69 patients with samples testing positive by PCR for the EML pathogen, samples from 6 were tested at a Figure 1 . Geographic distribution of the likely county in Minnesota or Wisconsin in which exposure to the Ehrlichia muris-like (EML) pathogen occurred in relation to the risk for Lyme disease, babesiosis, and anaplasmosis. The risk of tickborne disease is based on county-specific mean annual reported incidence of confirmed Lyme disease and confirmed and probable human anaplasmosis and babesiosis cases in Minnesota and Wisconsin during 2007-2013. Counties with ≤10 cases/100,000 population were classified as low risk; counties with 10-24.9 cases/100,000 population were classified as moderate risk; and counties with >25 cases/100,000 population were classified as high risk.
commercial laboratory for IgG-class antibodies to E. chaffeensis and A. phagocytophilum (Table 2; online Technical Appendix Table 2 ). For 1 patient, an acute sample collected 6 days after illness onset (reciprocal titer 512) and a convalescent sample collected 56 days after illness onset (reciprocal titer 1,024) tested positive for IgG-class antibodies to E. chaffeensis. For another patient, an acute sample collected 2 days after illness onset (reciprocal titer 64) tested positive for IgG-class antibodies to A. phagocytophilum (online Technical Appendix Table 2 ). For each of 15 patients whose samples tested positive by PCR for the EML pathogen, 2 thin blood films were examined by using light microscopy with oil immersion. No intraleukocytic morulae were identified in these films.
Clinical and Epidemiologic Features
Among the 69 EML-positive patients, 44 (64%) were male; age range was 15-94 (median 62) years (Table 2) . Patients reported symptom onset during April-December, with peak onset (52%) occurring in June and July (Figure 2 ). Thirteen (27%) of 49 patients with known immune status had immunocompromised conditions resulting from immunosuppressive therapies: 7 with solid organ allografts received immune modulating pathogens; 2 received chemotherapy to treat malignancy; and 4 received systemic steroids to treat an autoimmune disease (rheumatoid arthritis [n = 3] and mixed connective tissue disease [n = 1]). The most frequently noted signs and symptoms were fever (87%), malaise (76%), headache (67%), and myalgia (60%). Frequently noted laboratory findings among those tested included thrombocytopenia (67%), lymphopenia (53%), leukopenia (39%), anemia (36%), and elevated aspartate aminotransferase or alanine transaminase (78%) ( Table 2) . Two of 28 patients tested had positive serologic results for Borrelia burgdorferi.
The range of days from symptom onset to PCR testing was 0-145 (median 4) days; 59 (86%) of 69 cases were detected within 10 days, and 94% were detected within 21 days. One patient reported new onset of fatigue and sweats ≈4 months before testing, but because of a complex medical history, a more compressed period for EML infection could not be excluded. The hospitalization rate was 23% (16/69 patients), and length of stay was 2-15 (median 4) days (Table 2 ). All patients recovered. Of 68 patients with available treatment information, 66 (97%) received a course of doxycycline and 2 recovered without therapy.
Discussion
We report clinical and epidemiologic data for 69 symptomatic patients infected with the newly described EML pathogen, including 4 patients with previously reported cases (11) . All patients reported likely exposure to ticks in Minnesota or Wisconsin, and the EML pathogen was not detected in >16,000 patient samples from other US states that have high incidence of diseases caused by other tickborne pathogens transmitted by Ixodes spp. ticks. The relatively limited area where EML infections were likely acquired suggests that the EML pathogen may have a limited geographic distribution. This potential geographic focus is also supported by tick data in which the EML pathogen has been detected only among I. scapularis ticks from Minnesota and Wisconsin and not from I. scapularis and A. americanum ticks from other US states (Minnesota Department of Health; University of Wisconsin-Madison Department of Entomology; and US Army Department of Defense Human Tick Test Kit Program, unpub. data) (12, 14) . Additional testing of humans and ticks from regions outside the upper midwestern United States would be valuable for further defining the distribution of the EML pathogen.
Data accumulated to date indicate that the epidemiologic features and clinical signs and symptoms of infection with the EML pathogen are similar to those of anaplasmosis and ehrlichiosis caused by other pathogens. Illness onset peaked in June and July, consistent with infection occurring during peak I. scapularis nymph activity of May and June in Minnesota and Wisconsin. Infected patients were more frequently male (1.8:1), and average patient age was 61 years. Fever, malaise, headache, and myalgia were the most common symptoms; leukopenia, lymphopenia, thrombocytopenia, and elevated levels of hepatic transaminase were the most common laboratory findings, consistent with anaplasmosis and ehrlichiosis caused by E. chaffeensis and E. ewingii (1, 3, 15) . No intraleukocytic morulae were identified on peripheral blood films, suggesting that this method may not be sensitive enough to detect this infection. The type of leukocyte infected by the EML pathogen is unknown.
Among 49 patients with reported immunocompromised status, 13 (27%) were receiving systemic immunosuppressive therapy. This percentage of patients with immunocompromising conditions is higher than that previously reported among patients with anaplasmosis or other causes of ehrlichiosis (1, 8) . Consequently, immunocompromised patients may be particularly susceptible to infection with the (17) .
In summary, our findings indicate that human infection caused by the EML pathogen continues to occur. This pathogen should be considered among the differential diagnoses when tickborne diseases are suspected among residents of Minnesota or Wisconsin or among persons with histories of travel to either state. 
